This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-3426v1 69/8/3625    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holstege, H. Articles by Jonkers, J. Search for Related Content PubMed PubMed Citation Articles by Holstege, H. Articles by Jonkers, J.

High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer

¹ Division of Molecular Biology, ² Division of Experimental Therapy, and ³ Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands and ⁴ National Institute for Public Health and the Environment, Laboratory for Health Protection Research, Bilthoven, the Netherlands

Requests for reprints: Jos Jonkers, Division of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Phone: 31-20-5122000; Fax: 31-20-6691383; E-mail: j.jonkers{at}nki.nl.

Key Words: BRCA1 • TP53 • breast cancer • protein-truncating mutation

Approximately half of all hereditary breast cancers are compromised in their DNA repair mechanisms due to loss of BRCA1 or BRCA2 function. Previous research has found a strong correlation between BRCA mutation and TP53 mutation. However, TP53 mutation status is often indirectly assessed by immunohistochemical staining of accumulated p53 protein. We sequenced TP53 exons 2 to 9 in 21 BRCA1-related breast cancers and 37 sporadic breast tumors. Strikingly, all BRCA1-related breast tumors contained TP53 mutations, whereas only half of these tumors stained positive for p53 accumulation. Positive p53 staining correlates with the presence of TP53 hotspot mutations in both BRCA1-related and sporadic breast tumors. However, whereas the majority of sporadic breast tumors that stained negative for p53 accumulation had wild-type TP53, the majority of BRCA1-associated breast tumors that stained negative for p53 accumulation had protein-truncating TP53 mutations (nonsense, frameshift, and splice mutations). Therefore, the strong selection for p53 loss in BRCA1-related tumors is achieved by an increase of protein-truncating TP53 mutations rather than hotspot mutations. Hence, immunohistochemical detection of TP53 mutation could lead to misdiagnosis in approximately half of all BRCA1-related tumors. The presence of deleterious TP53 mutations in most, if not all, BRCA1-related breast cancers suggests that p53 loss of function is essential for BRCA1-associated tumorigenesis. BRCA1-related tumors may therefore be treated not only with drugs that target BRCA1 deficiency [e.g., poly(ADP-ribose) polymerase inhibitors] but also with drugs that selectively target p53-deficient cells. This raises interesting possibilities for combination therapies against BRCA1-deficient breast cancers and BRCA1-like tumors with homologous recombination deficiency. [Cancer Res 2009;69(8):3625–33]

This article has been cited by other articles:

				B. Evers, E. Schut, E. van der Burg, T. M. Braumuller, D. A. Egan, H. Holstege, P. Edser, D. J. Adams, R. Wade-Martins, P. Bouwman, et al. A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors Clin. Cancer Res., January 1, 2010; 16(1): 99 - 108. [Abstract] [Full Text] [PDF]

				M. Keimling and L. Wiesmuller DNA double-strand break repair activities in mammary epithelial cells--influence of endogenous p53 variants Carcinogenesis, July 1, 2009; 30(7): 1260 - 1268. [Abstract] [Full Text] [PDF]